特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

血友病希少因子市場 - 成長、傾向、予測

Rare Hemophilia Factors Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921266
出版日 ページ情報 英文 111 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.99円で換算しております。
血友病希少因子市場 - 成長、傾向、予測 Rare Hemophilia Factors Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 111 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、血友病希少因子の世界市場を調査し、市場の概要、タイプ、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概要
  • 成長要因
  • 抑制要因
  • ファイブフォース分析
    • 新規参入の脅威
    • 消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内での競争

第5章 市場セグメンテーション

  • 治療別
    • 因子濃縮
    • 新鮮凍結血漿(FFP)
    • クリオプレシピテート
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Baxter Healthcare
    • Bayer Healthcare
    • Bio Products Laboratory Ltd.
    • Biogen
    • CSL Behring
    • Novo Nordisk
    • Pfizer, Inc.
    • Takeda Pharmaceutical Co. Ltd.

第7章 市場機会および将来動向

目次
Product Code: 67120

Market Overview

Certain factors that are driving the market growth include rising adoption and approval of new treatment techniques, a growing number of government initiatives and funding.

The worldwide incidence of hemophilia is not well known but estimated at more than 400,000 people. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment. Scientists report that hemophilia is three times more prevalent in men worldwide than previously thought and still associated with a poorer life expectancy, especially in low-income countries. Findings of the study, "Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries," were published in the Annals of Internal Medicine. This observational study came in response to a call by the World Federation of Hemophilia to more accurately measure the disease's prevalence and its impact on life expectancy.

Scope of the Report

Hemophilia is a genetic bleeding disorder that prevents the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages.

Key Market Trends

Fresh frozen plasma (FFP) is Expected to Hold Significant Market Share in the Treatment Segment

Plasma transfusion is indicated for the management of bleeding or to prevent bleeding prior to an urgent invasive procedure in patients requiring replacement of multiple coagulation factors. Fresh frozen plasma is the fluid portion of a unit of whole blood that is frozen in a designated time frame, usually within 8 hours. FFP contains all coagulation factors except platelets. FFP contains fibrinogen (400 to 900 mg/unit), albumin, protein C, protein S, antithrombin, tissue factor pathway inhibitor. FFP can only be administered intravenously. FFP must be ABO compatible with the recipient's red cells. The FFP container and fluid upon visual inspection should have no leakage, clots, or abnormal color.

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the Center for Disease Control and Prevention (CDC), Hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals (National Hemophilia Foundation, 2018). In the United States, most people with hemophilia are diagnosed at a very young age. Based on CDC data, the median age at diagnosis is 36 months for people with mild hemophilia, 8 months for those with moderate hemophilia, and 1 month for those with severe hemophilia. In about two-thirds of cases, there is a family history of hemophilia. The diagnosis of hemophilia is made using a special blood test and most babies can be tested soon after birth. Sometimes prenatal genetic testing is done to diagnose hemophilia before birth (CDC, 2019).

Competitive Landscape

The global Rare Hemophilia Factors market is moderately competitive and consists of a number of major players. Companies like Baxter Healthcare, Bayer Healthcare, Bio Products Laboratory Ltd., Biogen, CSL Behring, Novo Nordisk, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., among others, hold the substantial market share in the Rare Hemophilia Factors market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption and Approval of New Treatment Techniques
    • 4.2.2 Growing Number of Government Initiatives and Funding
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Factor Concentrate
    • 5.1.2 Fresh frozen plasma (FFP)
    • 5.1.3 Cryoprecipitate
    • 5.1.4 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter Healthcare
    • 6.1.2 Bayer Healthcare
    • 6.1.3 Bio Products Laboratory Ltd.
    • 6.1.4 Biogen
    • 6.1.5 CSL Behring
    • 6.1.6 Novo Nordisk
    • 6.1.7 Pfizer, Inc.
    • 6.1.8 Takeda Pharmaceutical Co. Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS